Grace Therapeutics
GRCE
26 hedge funds and large institutions have $602K invested in Grace Therapeutics in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 12 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
0.09% less ownership
Funds ownership: 0.13% → 0.04% (-0.09%)
21% less funds holding
Funds holding: 33 → 26 (-7)
58% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 12
95% less capital invested
Capital invested by funds: $12.6M → $602K (-$12M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
+$91.4K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$35.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$35.3K |
| 4 |
SIAP
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
|
+$14.7K |
| 5 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$12.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$4.36M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.52M |
| 3 |
PP
Peconic Partners
New York
|
-$858K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$676K |
| 5 |
Renaissance Technologies
New York
|
-$252K |
GRCE Hedge Fund Activity: Q1 2020 in Review
26 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2020, worth a combined $602K — down 95% from $12.6M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of GRCE and 5 opened new positions — a net loss of 7 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Oppenheimer & Co, adding an estimated $91.4K. The largest seller was Perceptive Advisors, exiting entirely with an estimated $4.36M sold.
- 26 institutional investors held Grace Therapeutics (GRCE) as of Q1 2020, down from 33 in Q4 2019.
- Funds reported $602K of Grace Therapeutics stock for Q1 2020, down 95% quarter-over-quarter.
- 5 funds opened new Grace Therapeutics positions in Q1 2020 and 12 closed out, a net change of -7 holders.
- The largest Grace Therapeutics buyer in Q1 2020 was Oppenheimer & Co, an estimated $91.4K added.
- The largest Grace Therapeutics seller in Q1 2020 was Perceptive Advisors, an estimated $4.36M sold.
Based on aggregated 13F filings for Q1 2020.